Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus

Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus

Abstract Background Finerenone is a third-generation mineralocorticoid receptor antagonists, which has shown good cardiac function improvement in patients with type 2 diabetes in large-scale clinical trials. However, its specific role in diabetic cardiomyopathy remains unclear. We explored the poten...

Full description

Bibliographic Details
Main Authors: Tao Jin, Xiangrui Fu, Ming Liu, Fengshuang An
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Diabetic cardiomyopathy
Finerenone
MRA
Fibrosis
Apoptosis
PPAR
Online Access:https://doi.org/10.1186/s13098-023-01064-3

Similar Items

Similar Items